[31] CohenE, TortoriciM, KimS, Ⅱ trialofaxitinibinpatientswithvarioushistologicsubtypesofadvancedthyroidcancer:long-termoutcomesandpharmacokinetic/pharmacodynamicanalyses[J].CaChemotherPharmacol,2014,74（6）:1261-1270.
[32] LocatiL, LicitraL, CohenEE, : Phase2studywithpharmacokinetic/pharmacodynamicandquality-of-lifeassessments[J].Cancer,2014, 120（17）:2694-2703.
[33] SchlumbergerM, EliseiR, BastholtL, etal.PhaseⅡstudyofsafetyandefficacyofmotesanibinpatientswithprogressiveorsymptomatic, advancedormetastaticmedullarythyroidcancer[J].JClinOncol,2009, 27（23）:3794-3801.
[34] LimS, ChungW, ChoB, , multicenter, phaseIIstudyofdovitinibinadvancedthyroidcancer[J].EurJCancer,2015, 51（12）:1588-1595.
[35] PennellN, DanielsG, LynchT, [J].Thyroid, 2008, 18（3）:317-323.
[36] HaH, LeeJ, UrbaS, [J].Thyroid,2010, 20（9）:975-980.
[37] HoA, GrewalR, LeboeufR, -enhancedradioiodineuptakeinadvancedthyroidcancer[J].NEnglJMed,2013, 368（7）:623-632.
[38] TsaiJ, LeeJ, WangW, -Rafkinasewithpotentantimelanomaactivity[J].ProcNatlAcadSciUSA, 2008,105:3041-3046.
[39] RheaultT, StellwagenJ, AdjabengG, : aselectiveinhibitorofrafkinaseswithantitumoractivityagainstB-Raf-driventumors[J].ACSMedChemLett ,2013, 4:358-362.
[40] CabanillasM, PatelA, DanyshBP, :experienceinthyroidcancerandgeneralreviewoftoxicity[J].HormCancer, 2015Feb;6（1）:21-36.
哦豁，小伙伴们如果觉得倾城文选不错，记得收藏网址 或推荐给朋友哦~拜托啦 (>.<)
传送门：